- Patent office reversed a prior decision and will prevent generic competition for the drug when it comes to daily dosing of 10, 15 and 20mg, Bayer says in statement
- Ruling doesn’t affect 2.5mg dosing of the product
- Bayer got about half of its 4.5 billion euros ($5.2 billion) revenue for Xarelto in EMEA region last year, spokesman said in phone interview
- Majority of Xarelto sales in EMEA come from daily dosings of 10, 15 and 20mg, spokesman said
- Decision ...
Oct. 29, 2021, 9:40 AM